In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total Improvement Score at Week 52 versus placebo (P<0.001), met all nine key secondary endpoints, and showed effects as early as Week 4. Steroid-sparing was notable, with nearly twice as many patients in the 30 mg arm able to taper background corticosteroids. Additional analyses presented at AAD 2026 reported an 18.9% greater proportion of patients achieving itch remission by Week 4 and, among those with moderate-to-severe baseline skin disease, a 26.6% higher rate of functional skin remission versus placebo, with quality-of-life gains sustained through one year. The core development is twofold: publication of the VALOR results in the New England Journal of Medicine and FDA Priority Review for brepocitinib’s NDA in dermatomyositis, with a PDUFA target in Q3 2026. VALOR randomized patients 1:1:1 to brepocitinib 30 mg, 15 mg, or placebo across 90 global sites and enrolled a heterogeneous DM population, including patients with prior neoplasms and multiple cardiovascular risk factors. More than two-thirds of patients on 30 mg achieved TIS40, and over half reached TIS40 while tapering to ≤2.5 mg/day prednisone-equivalent. Safety showed higher serious infections with 30 mg versus placebo that were generally managed medically, while discontinuations, malignancies, cardiovascular, and thromboembolic events were numerically higher on placebo—differences the publication attributes to baseline disease and steroid-related risk. The broader safety database (>2,000 exposed) suggests a profile in line with approved JAK and TYK2 inhibitors.
Strategically, this positions Priovant to challenge a steroid- and IVIG‑anchored DM treatment paradigm with an oral, targeted option built around a steroid-sparing narrative. The dual TYK2/JAK1 mechanism aligns with the cytokine biology of DM and offers operational simplicity relative to combination regimens and infusion-based approaches. NEJM visibility and a clean sweep of secondary endpoints strengthen the case with guideline bodies and payers at a time when regulators are pressing sponsors to limit chronic steroid exposure. The counterweight is the class safety overhang attached to JAK‑pathway agents; Priority Review accelerates timelines but does not resolve labeling, boxed warning scope, or potential postmarketing commitments.
For research sites and CROs, VALOR demonstrates that global enrollment of a comorbidity‑heavy DM population is feasible with composite endpoints and integrated PROs, setting a template for future myositis protocols. Dermatology–rheumatology co-management will be central to real‑world adoption, and the prominence of skin endpoints and itch relief may shift site assessments and ePRO capture earlier in the course. Infusion centers and IVIG suppliers could see demand pressure if an oral alternative proves durable and payer-accessible, while sponsors active in rare autoimmune will note the traction of steroid-sparing outcomes as a regulatory and commercial lever. Payers will focus on the magnitude and durability of tapering, the potential to offset IVIG utilization, and any risk-management requirements.
Ahead of the PDUFA date, the key watch points are label breadth across systemic and cutaneous domains, the nature of class warnings and any REMS, and whether FDA explicitly recognizes steroid-sparing as a claim. Post-approval, guideline incorporation by myositis consortia and payer criteria will dictate uptake speed. Operationally, Priovant will need to build a field footprint across dermatology and rheumatology, ensure pharmacovigilance resources suited to JAK‑pathway scrutiny, and ready real-world evidence programs focused on flare control and corticosteroid reduction. Pipeline read-throughs from Priovant’s Phase 3 uveitis and the planned Phase 3 in cutaneous sarcoidosis will indicate whether the dual TYK2/JAK1 strategy can extend beyond DM. Competitive pressure will come from off‑label JAKs and entrenched IVIG; the decisive factor will be sustained benefit with acceptable safety and payer alignment on steroid minimization.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
